C. Martorell

发表

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

H. Stellbrink, P. Sax, H. Albrecht, 2019, The lancet. HIV.

Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment

F. Post, M. Ramgopal, M. Fisher, 2014, HIV clinical trials.

Randomized Study of Asunaprevir plus Pegylated Interferon-α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C

K. Reddy, P. Thuluvath, S. Pol, 2013, Antiviral therapy.

A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

P. Thuluvath, E. Lawitz, R. Ghalib, 2015, Journal of viral hepatitis.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials†

H. Stellbrink, M. Das, E. Daar, 2018, HIV medicine.

Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

D. Potvin, S. Grinspoon, D. Berger, 2010, Journal of acquired immune deficiency syndromes.

Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non‐adherence

A. Luetkemeyer, D. Wyles, M. Sulkowski, 2020, Alimentary pharmacology & therapeutics.

Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.

J. Currier, M. Yin, J. Mrus, 2011, AIDS patient care and STDs.

Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women.

J. Garb, C. Martorell, K. Oie, 2010, The Pediatric infectious disease journal.

1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

P. Thuluvath, S. Pol, D. Larrey, 2012 .

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS

P. Thuluvath, G. Everson, S. Pol, 2011 .

Preliminary study of two antiviral agents for hepatitis C genotype 1.

Anna Persson, Vinod Rustgi, A. Lok, 2012, The New England journal of medicine.

1189 ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL

G. Everson, S. Pol, C. Hézode, 2010 .

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

A. Lok, G. Everson, D. Grasela, 2011 .

2005 VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS

I. Jacobson, E. Lawitz, J. Lalezari, 2010 .

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1

I. Jacobson, E. Lawitz, J. Lalezari, 2009 .

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.

P. Thuluvath, S. Pol, V. Ratziu, 2014, Journal of hepatology.

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor

M. Ramgopal, G. Moyle, M. Fisher, 2014, Journal of the International AIDS Society.

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

S. Mallal, M. Saag, E. Phillips, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Ulysses Diva, Vinod K Rustgi, P. Thuluvath, 2012, The Lancet. Infectious diseases.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.

D. Podzamczer, H. Stellbrink, P. Sax, 2020, The lancet. HIV.

Use of HIV Resistance Testing After Prolonged Treatment Interruption

D. Skiest, D. Iarikov, R. Hoffman, 2010, Journal of acquired immune deficiency syndromes.

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

A. LaMarca, H. Stellbrink, F. Post, 2017, The lancet. HIV.

Low Prevalence of Primary HIV Resistance in Western Massachusetts

D. Skiest, D. Iarikov, R. Hoffman, 2010, Journal of the International Association of Physicians in AIDS Care.

HIV/AIDS and the Latino Populations in the U.S.: Epidemiology, Prevention, and Barriers to Care and Treatment

C. Martorell, 2009 .

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

P. Thuluvath, G. Everson, S. Pol, 2012, The Lancet. Infectious diseases.